ID
32041
Description
Study ID: 105229 Clinical Study ID: GLP105229 Study Title: A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2
Mots-clés
Versions (1)
- 15/10/2018 15/10/2018 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
15 octobre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Subcutaneous injections of GSK 716155 in healthy volunteers; Study ID: 105229
Similar models
Hypoglycaemic Events
- StudyEvent: ODM
C0808070 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
C1522314 (UMLS CUI [1,2])
C0578574 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0202042 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,4])
C0332152 (UMLS CUI [1,2])
C0202042 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,4])
C0202042 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,3])
C0202042 (UMLS CUI [1,2])
C1519795 (UMLS CUI [1,3])
C0439603 (UMLS CUI [1,2])
C1547647 (UMLS CUI [1,2])
C0184661 (UMLS CUI [1,2])
C0518690 (UMLS CUI [1,2])
C1704758 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,2])
C1521721 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C2349954 (UMLS CUI [1,2])